NX-1207 not effective in treatment of BPH

As regular readers will be aware, Nymox Pharmaceutical has been developing a drug called NX-1207 for the treatment of benign prostatic hypertrophy (BPH) and for the treatment of localized prostate cancer. The drug has been in different Phase III trials for each possible use.

NX-1207 is a drug that is injected directly into the prostate, making it very different to almost any other available or investigational form of treatment for either BPH or prostate cancer.

Over the weekend, however, the company apparently announced that NX-1207 is not effective in the treatment of BPH.  This does not mean that it may not be effective in the treatment of localized prostate cancer — but it does tend to cast some more doubt on that possibility.

As of 07:25 a.m. EST this morning, the company’s full statement has not been posted to its web site.

One Response

  1. There is now another phase III trial, re-injection of NX-1207 for BPH.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: